Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Good Manufacturing Practices01:26

Good Manufacturing Practices

Good Manufacturing Practices (GMP) constitute a foundational set of guidelines that ensure the production of safe, consistent, and high-quality products, particularly in industries such as pharmaceuticals, biotechnology, and food processing. These protocols encompass all aspects of production, from the sourcing of raw materials to the final distribution of the finished product.A core pillar of GMP is stringent hygiene and sanitation across all production environments. This includes routine...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Karyotyping01:17

Karyotyping

Describing the number and physical features of chromosomes can reveal abnormalities that underlie genetic diseases. This description is facilitated by special staining techniques that produce a particular banding pattern on each chromosome. State-of-the-art techniques make this approach even more powerful, enabling the detection of individual genes that cause disease.A Simple Chromosome Staining Technique Provides Valuable Scientific InsightSome genetic diseases can be detected by looking at...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Phosphorylation01:02

Phosphorylation

The addition or removal of phosphate groups from proteins is the most common chemical modification that regulates cellular processes. These modifications can affect the structure, activity, stability, and localization of proteins within cells as well as their interactions with other proteins.
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New European guidance on borderline products.

Medical device technology·2009
Same author

The evolving process of European combination product review, Part II.

Medical device technology·2009
Same author

The evolving process of European combination product review, Part I.

Medical device technology·2008
Same author

FDA draft guidance on computerised systems used in clinical trials.

Medical device technology·2005
Same author

The essential element of ethics.

Medical device technology·2004
Same author

Guidance on submitting quality system information.

Medical device technology·2004
Same journal

Safer arterial access.

Medical device technology·2010
Same journal

Building better surfaces.

Medical device technology·2010
Same journal

PVC: a broader perspective.

Medical device technology·2010
Same journal

Joining and forming using torsional ultrasonic principles.

Medical device technology·2010
Same journal

US regulation of combination products.

Medical device technology·2010
Same journal

Assessing biological safety of metals associated with medical devices.

Medical device technology·2010
See all related articles

Related Experiment Video

Updated: Jul 3, 2026

Metal-Assisted Electrochemical Nanoimprinting of Porous and Solid Silicon Wafers
09:18

Metal-Assisted Electrochemical Nanoimprinting of Porous and Solid Silicon Wafers

Published on: February 8, 2022

Who owns the 510(k)?

Maria E Donawa1

  • 1Donawa Consulting, Rome, Italy. medonawa@donawa.com

Medical Device Technology
|July 9, 2008
PubMed
Summary
This summary is machine-generated.

Many international medical device manufacturers are unaware of the business implications when submitting a 510(k) premarket notification to the US Food and Drug Administration (FDA). This article clarifies ownership and business aspects of the FDA 510(k) filing process.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

Related Experiment Videos

Last Updated: Jul 3, 2026

Metal-Assisted Electrochemical Nanoimprinting of Porous and Solid Silicon Wafers
09:18

Metal-Assisted Electrochemical Nanoimprinting of Porous and Solid Silicon Wafers

Published on: February 8, 2022

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

Area of Science:

  • Regulatory Affairs
  • Medical Device Business

Background:

  • Many medical device manufacturers, especially those outside the US, lack awareness of the business implications associated with the 510(k) premarket notification process.
  • Understanding the business and ownership aspects of FDA submissions is crucial for successful market entry.

Purpose of the Study:

  • To inform medical device manufacturers about the business and ownership considerations when filing a 510(k) with the US Food and Drug Administration.
  • To provide clarity on the non-scientific aspects of the 510(k) submission process.

Main Methods:

  • Review of regulatory guidelines pertaining to 510(k) submissions.
  • Analysis of business and ownership structures relevant to FDA filings.
  • Discussion of common challenges faced by international manufacturers.

Main Results:

  • Identification of key business implications often overlooked by manufacturers.
  • Clarification of ownership structures and their impact on the 510(k) process.
  • Highlighting the importance of proactive business planning for regulatory submissions.

Conclusions:

  • Manufacturers must be cognizant of business and ownership factors beyond the technical aspects of their devices.
  • Thorough understanding of these elements can prevent delays and ensure compliance with US FDA regulations.
  • Strategic business planning is integral to navigating the 510(k) pathway effectively.